Autoimmune Disease Treatment Market Overview, Analysis and Regional Insights
- Get link
- Other Apps
In 2012, the National Institute of Health (NIH) estimated that around 23.5 million Americans have an autoimmune illness. Furthermore, the Department of Health and Human Services revealed in 2017 that autoimmune disease (AID) is placed #1 among the top 10 health topics. Autoimmune disease has a significant impact on one's health, and it can result in a variety of difficulties in numerous parts of the body, including the heart, brain, kidneys, glands, and nerves. Autoimmune disease is becoming more common due to genetic and environmental variables such as dietary components, toxic chemicals, and infections. Irritable bowel disease (IBD), rheumatoid arthritis (RA), multiple sclerosis (MS), celiac disease (CD), hepatitis, autoimmune thyroiditis (AT), systemic lupus erythematosus (SLE), and type 1 diabetes are all autoimmune disorders (IDDM).
Due to a lack of basic knowledge about
the illness pattern, identifying treatments, and designing clinical trials,
diagnosing AID is difficult. The expansion of the autoimmune
disease treatment market is projected to be aided by increased public
awareness of autoimmune disorders and its implications.
Autoiommune Disease Treatment Market
Advanced approaches for the treatment of AID
is expected favor the growth of autoimmune disease treatment market
The autoimmune disease treatment
industry is projected to benefit from advancements in AID treatment. In 2016,
researchers at the Perelman School of Medicine discovered a strategy to target
a specific fraction of antibody that is responsible for the activation of the
autoimmune illness pemphigus vulgaris (PV). The researchers developed chimeric
autoantibody receptor treatment (CAART), which can be utilised to treat this
disease without affecting the immune system's normal function.
Furthermore, in 2016, Cumming School
of Medicine researchers discovered a new class of Nano-medicine to treat
diseases such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis
without affecting immunity. Parvus Therapeutics, Inc. is currently developing
this Nano-medicine, which is being financed by Innovate Calgary.
- Get link
- Other Apps
Comments
Post a Comment